Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project

Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project

Background Off-label use (OLU) of a drug reflects a perceived unmet medical need, which is common in oncology. Cancer drugs are often highly expensive and their reimbursement is a challenge for many healthcare systems. OLU is frequently regulated by reimbursement restrictions. For evidence-based hea...

Full description

Bibliographic Details
Main Authors: Matthias Briel, Lars G Hemkens, Amanda Katherina Herbrand, Andreas Michael Schmitt, Stefan Diem, Hannah Ewald, Anouk Hoogkamer, Markus Joerger, Kimberly Alba Mc Cord, Urban Novak, Sirintip Sricharoenchai, Benjamin Kasenda
Format: Article
Language:English
Published: Elsevier 2019-11-01
Series:ESMO Open
Online Access:https://esmoopen.bmj.com/content/4/6/e000596.full

Internet

https://esmoopen.bmj.com/content/4/6/e000596.full

Similar Items